MEIRAGTX HOLDINGS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.39 USD | +4.86% |
|
+0.56% | -22.93% |
| May. 09 | Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000 | MT |
| May. 09 | MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 69.81M | Sales 2025 * | 273M | Capitalization | 331M |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | 154M | EV / Sales 2024 * | 4.73 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.21 x |
| P/E ratio 2024 * |
-3.32
x | P/E ratio 2025 * |
11
x | Employees | 402 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on MeiraGTx Holdings plc
More recommendations
More press releases
| 1 day | +4.86% | ||
| 1 week | +0.56% | ||
| Current month | +10.86% | ||
| 1 month | -1.10% | ||
| 3 months | -14.26% | ||
| 6 months | +11.78% | ||
| Current year | -22.93% |
1 week
4.95
5.59
1 month
4.685.65
Current year
4.687.57
1 year
3.498.35
3 years
3.4924.89
5 years
3.4930.23
10 years
3.4930.23
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Giroux
FOU | Founder | 61 | 15-03-19 |
| Chief Executive Officer | 59 | 15-03-19 | |
Robert Zeldin
CTO | Chief Tech/Sci/R&D Officer | 61 | 20-08-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 22-04-24 |
Thomas Shenk
BRD | Director/Board Member | 77 | 15-05-31 |
Keith Harris
CHM | Chairman | 71 | 15-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +9.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 5.555 | +8.07% | 8 979 |
| 24-05-13 | 5.14 | +1.38% | 80,045 |
| 24-05-10 | 5.07 | -0.59% | 104,790 |
| 24-05-09 | 5.1 | -0.78% | 83,726 |
| 24-05-08 | 5.14 | -4.46% | 105,172 |
Delayed Quote Nasdaq, May 14, 2024 at 09:34 am EDT
More quotes
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.14
USD
Average target price
21.2
USD
Spread / Average Target
+312.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.93% | 331M | |
| +5.53% | 111B | |
| +11.01% | 105B | |
| -11.88% | 22.34B | |
| -3.23% | 21.93B | |
| -5.94% | 18.59B | |
| -36.52% | 18.12B | |
| -10.32% | 16.96B | |
| +3.77% | 13.7B | |
| +37.65% | 12.45B |
- Stock Market
- Equities
- MGTX Stock